Merck Pulls Plug On Acquired Drug after Safety Review
Source: Benzinga ·

Merck & Co. Inc. (NYSE:MRK) on Tuesday announced the discontinuation of the clinical development program evaluating nemtabrutinib (MK-1026), an investigational, oral, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor. Nemtabrutinib is being evaluated for patients with chronic
Read the full story at Benzinga
Shared from the GodsView world desk: live wires next to a globe of flights, ships, fires, and quakes.